Drug intelligence / Profile preview

UNEX-42

Development stage
Discontinued
Lead developer
United Therapeutics
Modality
Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intratracheal, Intravenous
01

Overview

UNEX-42 (unexisome) is an exosome-based therapeutic candidate consisting of extracellular vesicles (EVs) derived from human bone marrow mesenchymal stem cells (BMSCs). Developed by United Therapeutics, it is currently being investigated in clinical trials for the prevention and treatment of bronchopulmonary dysplasia (BPD) in extremely preterm neonates. The therapy functions by delivering a complex cargo of bioactive molecules, including proteins, lipids, and various RNA species, which exert paracrine effects to modulate inflammatory responses, reduce fibrosis, and promote alveolar and vascular growth in the developing lung. By leveraging the regenerative properties of MSC-derived vesicles without the risks associated with whole-cell transplantation, UNEX-42 aims to mitigate the lung injury caused by mechanical ventilation and oxygen toxicity in high-risk infants.

Other names
unexisomebone marrow mesenchymal stem cell-derived extracellular vesiclesBMSC-EVs

Beyond the preview

Go deeper on UNEX-42.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UNEX-42.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call